In this clinical trial we will test a new approach for decolonization of S. aureus.
As innovative product HY-133 a recombinant chimeric bacteriophage endolysin will be sprayed in both nostrils of healthy subjects once or five times in one day. To avoid possible bias the subjects will be randomized 3:2 verum vs placebo, moreover the subject as well as the investigator will be blinded to the group assigned.
Must be ≥ 18 years at the time of signing the informedconsent.
Understand and voluntarily sign an informed consent document prior to any study related
assessments/procedures.
Nasal colonization with methicillin-susceptible S. aureus (MSSA)
Nasal colonization with methicillin-resistant S. aureus (MRSA)
Nasal traumata including nose penetrating foreign bodies (e.g. piercings)
Presence of any significant morbidity, e.g. Diabetes, cardiovascular disease
Acute or known chronic diseases of the nose or the paranasal sinuses